Figure 1
From: Targeting DNA-PKcs and telomerase in brain tumour cells
MST-312 binds to DNA and inhibits telomerase activity in brain cancer cells. (A) Medulloblastoma cells, ONS76, were treated with indicated doses of MST-312 for 48 hours and examined for telomerase activity by TRAP assay. (B) Glioblastoma cells, MO59K and KNS60, were treated with low dose of MST-312 for 48 hours and examined for telomerase activity. (C) Brain tumour cells were treated with 1.0 μM MST-312 for 48 hours and the expression of hTERT was determined by western blot. (D) MO59K cells treated with 1.0 μM MST-312 for 48 hours were grown in fresh media for 72 hours and telomerase activity was determined. Days refer to the number of recovery days post 48 hours treatment with 1.0 μM MST-312. (E) Genomic DNA was extracted from ONS76 cells and binding affinity of MST-312 to DNA determined with ITC assay. ITC assay demonstrated that MST-312 has strong binding affinity to DNA (right panel) demonstrated by the increase in the amount of heat released (bond formation) when normalised with control (left panel). Means and standard errors (SE) from three independent experiments are presented. *Represents statistically significant (p <0.05) in comparison to the respective DMSO treatments.